Summary Introduction
The human herpesviruses are among the world's most ubiquitous infections, with almost all eight viruses infecting the majority of the global population. While there is some heterogeneity in the prevalence of these infections in different populations, only one shows a curious pattern of both geographic and demographic restriction. Human herpes virus 8 (HHV-8, also known as KSHV), was first identified as the etiologic agent of KS in 1994 1 , and is now known to be prevalent in populations of men who have sex with men (MSM), as well as persons from the Southern Mediterranean, Middle East, Africa, and parts of South America and Asia [2] [3] [4] [5] .
The reason for these distinct "pockets" of infection has not been wellcharacterized. Epidemiologic and virologic data suggest that HHV-8 is transmitted predominantly through saliva [6] [7] [8] [9] , similar to other human herpesviruses such as HSV-1, EBV, CMV, and HHV-6. It has been hypothesized that the relative restriction of HHV-8 infection may be attributable to differences across populations in susceptibility to infection, control of viral replication at mucosal sites, and/or behavioral, biologic or infectious co-factors for acquisition.
Prevalence of HHV-8-associated Disease
Infection with HHV-8 is most frequently asymptomatic 10 , but may progress to one of three neoplastic or lymphoproliferative disorders: KS, multicentric Castleman disease (MCD), or PEL 11 . The burden of HHV-8-associated disease is greatest in areas where HHV-8 infection is endemic 12 . However, while HHV-8 infection is required for development of KS, PEL or some forms of MCD, it is not likely to be sufficient. The presence of co-factors such as immunosuppression may enhance progression to disease 13 , and therefore there are clear disparities between the prevalence of HHV-8 infection and the incidence of KS. For example, countries in Africa have among the highest incidence of KS in the world, but the incidence varies widely even in countries with a similar seroprevalence of HHV-8 and HIV infection ( Figure 1 ).
KS is the commonest HHV-8-associated disease. In the height of the HIV epidemic, 1 in 5 HIV-infected persons in the USA developed KS 13 , though the incidence has dropped dramatically with the introduction of highly active antiretroviral therapy (HAART) 14 . Today, KS remains the most frequent malignancy in persons with HIV in the USA 14 . In many parts of Africa, KS is the most common cancer in the entire population 12 , and KS likely accounts for 1% of all cancers in resource-poor areas 15 . MCD and PEL remain relatively rare complications of HHV-8 infection. No comprehensive registry tracks the incidence of these diseases, and thus their frequency in the population is difficult to ascertain. It is estimated that less than 10,000 people are afflicted with MCD in the USA 16 , with even fewer cases of PEL under medical care. important to note that many who "respond" to conventional chemotherapy will still have residual disease. Considerably less information is available regarding the treatment of MCD and PEL. In small case series, treatment of these diseases with conventional chemotherapy has been associated mostly with short-lived responses and high mortality 16, 20 .
Efficacy and Limitations of Current Treatment Strategies

Therapies Under Investigation
The limited response rates and significant toxicity seen with conventional adjunctive chemotherapy have spurred investigators to search for novel therapeutics for the treatment and prevention of HHV-8-associated disease.
Antiviral Therapy
In each of the HHV-8-associated diseases, ongoing viral replication plays a key role in the development or sustenance of disease. The presence of replicating HHV-8 in the peripheral blood has been shown to be one of the strongest predictors for the development of KS [21] [22] [23] [24] , and in vitro work has revealed that a small amount of lytic HHV-8 infection is required for the initiation and maintenance of KS tumors 25 . MCD is characterized by episodic reactivation of HHV-8 replication, accompanied by high levels of HHV-8 in the peripheral blood 26 and an almost exclusively lytic viral gene program 27 .
PEL falls somewhere between KS and MCD in the spectrum of lytic replication 27 . These observations imply that antiviral therapy aimed at abrogating HHV-8 replication may have a role in the prevention or treatment of HHV-8-associated disease.
In 1978, a safe and effective compound was developed with considerable activity against the human herpesviruses 28 . In the subsequent three decades, a series of DNA synthesis inhibitors were developed with variable activity against each of the 8 human herpesviruses 29 . Data supporting the efficacy of antiviral medications in suppressing HHV-8 replication come from both basic science and observational studies.
The herpesvirus DNA synthesis inhibitors rely on the ability of a nucleoside analogue to be incorporated into a growing viral DNA chain. The different antiherpetic antivirals differ in their mechanism of action. Aciclovir, penciclovir, famciclovir, and ganciclovir all are phosphorylated by the herpesvirus thymidine kinase (TK) and/or UL97 phosphotransferase 30 , though each herpesvirus enzyme may have a different affinity for each nucleoside analogue. Foscarnet and cidofovir both work independently of the herpesvirus TK /UL97; the former acts directly on the pyrophosphate binding site of the DNA polymerase while the latter is diphosphorylated by cellular enzymes. In the first set of analyses to determine whether any of the current antiviral agents would be active against HHV-8, it was found that the HHV-8 TK and PT share homology with those in other human herpesviruses, and that they are capable of phosphorylating ganciclovir 31 .
Subsequently, a set of novel experiments were designed to test the antiviral susceptibility of HHV-8 in vitro. These new methods were required because the virus does not produce a cytopathic effect in culture, obviating the traditional "gold standard' for susceptibility testing, the plaque reduction assay. Though these experiments differed in their methodology, most measured the degree to which a given antiviral would reduce the production of HHV-8 lytic gene products (either viral DNA or lytically-expressed proteins) when added to a cell culture containing an immortalized, latently-infected HHV-8 cell line induced to lytic replication. The results were uniformly consistent in that ganciclovir, foscarnet and cidofovir were the only agents with activity against HHV-8
32-
36 . HHV-8 research is also hampered by the lack of a facile animal model, but productive infection may be established in immunocompromised mice, and this infection is blocked by administration of ganciclovir immediately after inoculation with HHV-8 37 .
Evidence supporting the efficacy of antiviral medication in the prevention or treatment of HHV-8-associated disease in humans is found either in retrospective studies or case series. Two separate retrospective studies found that the incidence of KS was significantly reduced among persons who had received foscarnet or ganciclovir for CMV retinitis, but no reduction in KS was seen among users of aciclovir 38, 39 . Similarly, a study investigating the efficacy of systemic ganciclovir for the treatment of CMV retinitis in AIDS patients found substantial reductions in the incidence of KS among persons treated with the drug, though this outcome was a secondary endpoint and no measurements of HHV-8 replication were obtained 40 .
In the first and only clinical trial to date to evaluate the effect of antiviral medication on HHV-8 replication, 26 HHV-8 infected men (including 16 with HIV and 10 without) were randomized to either oral valganciclovir, 900 mg daily, or placebo once daily for 8 weeks 41 . After a 2-week washout period, participants were randomized to the opposite treatment arm for an additional 8 weeks. Oral swabs were collected for the quantification of HHV-8 DNA by PCR daily throughout the 18-week study. The use of valganciclovir was associated with a 46% reduction in oral HHV-8 replication (Figure 2 ), an effect that was found to be independent of the reduction in CMV replication.
Only one trial has evaluated the use of antiviral medication for the treatment of KS, finding that cidofovir was ineffective by itself for the treatment of both epidemic and classic KS 42 . Interferon-alpha, which has both antiviral and immunomodulatory properties, however, may find a role as adjunctive therapy in persons with advanced KS.
Five (38%) of 13 patients with epidemic KS responded to interferon-alpha 2b in conjunction with HAART 43 .
Although KS is more common, it might be expected that the HHV-8-associated diseases which are characterized by more extensive viral replication would be the best candidates for treatment with antiviral therapy. Successful treatment of PEL, either alone or with adjunctive chemotherapy, immunotherapy, or HAART, has been described to date with both ganciclovir 44, 45 and cidofovir 44, 46, 47 . Of note in some of these case series is a documented decline in HHV-8 viral load coinciding with administration of antiviral therapy 44, 46 , and in one case, rebound with gaps in therapy 44 . Similar results have been observed in MCD patients treated with ganciclovir 48, 49 , but failures have been reported with cidofovir 50 . Recent basic science data also find that it may be feasible to induce cells latently-infected with HHV-8 to lytic replication with valproic 51 or glycyrrhizic 52 acid or bortezomib 53 , thereby "sensitizing" the tumor to antiviral therapy. Several clinical trials are currently enrolling patients to assess the efficacy of antiviral or inductive therapy in the treatment of HHV-8-associated disease
Novel Chemotherapy
In the effort to make chemotherapy more effective and less toxic, great progress has been made in the past decade to target specific molecules involved in oncogenesis.
Many HHV-8-associated conditions exhibit features making them ideal targets for molecularly-directed therapy 54 .
Vascular Endothelial Growth Factor Inhibitors. KS is among the most vascular
tumors, and the interactions between HHV-8 and the human vascular endothelial growth factor (VEGF) pathway are essential for tumorigenesis. VEGF receptors 2 and 3 are expressed in KS lesions 55 , and HHV-8 glycoproteins K1 and glycoprotein B (gB) increase the expression of VEGF and activate VEGF-R3 (respectively) 56, 57 . Clinical trials of early VEGF inhibitors, pentosan and tecogalan, were characterized by moderate toxicity and minimal efficacy [58] [59] [60] . A phase II study of IM862, an antiangiogenic compound which both inhibits VEGF formation and activates natural killer cells, showed that 36% of 44 patients with epidemic KS had at least a partial response 61 . Of note, no relationship between plasma VEGF levels and either administration of IM862 or tumor response could be identified, suggesting that either the effects were local or the drug worked in a manner independent of VEGF. A subsequent Phase III placebo controlled study, however, found the drug to be no more efficacious than HAART alone, suggesting that the efficacy seen in the Phase II study may have been attributable to HAART use 62 .
A Phase I study of a novel antisense oligonucleotide to VEGF (VEGF-AS) led to more dramatic decreases in VEGF plasma levels and a complete remission of KS in a patient who was refractory to chemotherapy and HAART, but dose-limiting toxicities were common 63 .
Tyrosine Kinase Inhibitors. The observation that KS tumors express c-kit, the tyrosine kinase receptor for stem cell factor, suggested to some that HHV-8-associated malignancies may be treatable with c-kit inhibitors 64 . Limited experience with imatinib showed that 5 of 10 patients with epidemic KS displayed a partial response to the drug, though diarrhea limited the dose of imatinib which could be administered in 6 of 10 participants 65 . Clinical trials are currently ongoing to examine the role of other c-kit inhibitors, such as sorafenib, in the treatment of KS.
Monoclonal Antibody Therapy. Deciphering the unique pathobiology of MCD has revealed two targets against which monoclonal antibody therapy could be effectively directed. Many of the signs and symptoms of MCD may be mediated by the production of viral IL-6, an analogue of the human cytokine which has been pirated by HHV-8. In an animal model, it has been shown that the expression of IL-6 in mice produces a disease which histologically and clinically resembles MCD 66 . Furthermore, high levels of IL-6
are universally detected in patients with HHV-8-assocaited MCD 26 . Administration of a murine monoclonal antibody against IL-6 to a patient with MCD resulted in a dramatic resolution of symptoms and signs, but the illness rapidly returned after the infusion was discontinued 67 . Subsequently, a humanized antibody to the IL-6 receptor was developed and was administered to 28 patients with the plasma cell variant of MCD in Japan 68 . Two of these participants were infected with HHV-8, and none had HIV. 12 (52%) of 23 participants who had lymphadenopathy saw a significant reduction in the size of their lymph nodes at one year, and C-reactive protein levels normalized in 18 (64%) of 28.
This study represents the largest clinical trial of person with MCD to date; the reasonable efficacy, and lack of serious adverse reactions, makes IL-6 receptor antagonists a promising choice for the treatment of MCD. The role of IL-6 in other HHV-8-associated diseases is less clear, but it is unlikely that these drugs will find indications in either PEL or KS. However, both MCD and PEL are primarily diseases of B lymphocytes.
Consequently, monoclonal antibody therapy (rituximab) directed at CD20, expressed on all mature B-cells (Figure 3 ), has been used successfully in the treatment of both MCD and PEL [69] [70] [71] [72] [73] [74] [75] [76] [77] .
Matrix Metalloproteinases. Matrix metalloproteinases (MMP) are overexpressed in KS
tumors, and may play a role in oncogenesis by helping the tumor to invade the basement membrane. COL-3 is a topical MMP inhibitor which is similar in structure to tetracycline. In a Phase II clinical trial comparing 2 doses of COL-3, 41% of 75 patients responded to the lower (50 mg) dose 78 . Participants frequently discontinued using the drug, and photosensitivity was common.
Summary
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